Neovascular glaucoma treatment

Neovascular glaucoma is a severe pathology of the eye, which is difficult to treat. It is characterized by rapid progression, high intraocular pressure (IOP) level, severe pain and an acute decrease in visual acuity. Its most common causes include diabetic retinopathy and ischemic central retinal vein occlusion. The endothelial vascular cells respond to a specific stimulus (tissular hypoxia) and secrete proangiogenic factors. The most significant is VEGF. The resulting imbalance between pro- and antiangiogenic factors produces neovascularization of the eye tissues. Panretinal photocoagulation and anti-VEGF therapy are used to reduce iris neovascularization and reduce the complications of surgical treatment. Currently, surgical methods such as trabeculectomy and tubular drainage implantation are used to treat neovascular glaucoma. An alternative to surgical interventions is presented by cyclodestructive procedures. Transscleral diode-laser micropulse cyclophotocoagulation is the latest technology, characterized by the absence of a pronounced damaging effect on tissues and a small number of complications.

1. Browning D.J. Retinal vein occlusions. Evidence-based management. Springer Science + Business Media New York; 2012. 387 p. doi: 10.1007/978-1-4614-3439-9.

2. Joussen A.M., Gardner T.W., Kirchhof B., Ryan S.J. (Eds.) Retinal vascular disease. Berlin, Heidelberg: Springer-Verlag; 2007. 778 p.

3. Balalin S.V., Efremova T.G., Potapova V.N. Application of anti-VEGF drugs and trans-scleral cyclophotocoagulation in the treatment of neovascular glaucoma with diabetes mellitus. Practical medicine; 2016; 98(6):12–14. (In Russ.).

4. Nesterov A.P. Glaukoma [Glaucoma]. Moscow, MIA; 2014. 360 p. (In Russ.).

5. Glaukoma: natsional'noe rukovodstvo [Glaucoma: national leadership]. Eds by E.A. Egorov. Moscow: GEOTAR-Media; 2013. 824 p. (In Russ.).

6. Hayreh S.S. Neovascular glaucoma. Prog Retin Eye Res. 2007; 26(5): 470-485. doi: 10.1016/j.preteyeres.2007.06.001

7. Lipatov D.V., Chistyakov T.A. Medical, laser and surgical treatment of secondary neovascular glaucoma in patients with diabetes. Glaucoma. 2013; 2:62-69. (In Russ.).

8. Dedov I.I., Shestakova M.V., Vikulova O.K., Zheleznyakov A.V. Diabetes mellitus in russian federation: prevalence, morbidity, mortality, parameters of glycaemic control and structure of glucose lowering therapy according to the federal diabetes register, status 2017. Diabetes Mellitus. 2018; 21(3):144-159. (In Russ.). doi:10.14341/DM9686

9. Lipatov D.V., Vikulova O.K., Zheleznyakova A.V., Isakov M.A. Trends in the epidemiology of diabetic retinopathy in russian federation according to the federal diabetes register (2013–2016). Diabetes Mellitus. 2018; 21(4):230-240. (In Russ.). doi:10.14.341/DM9797

10. Fong D.S., Aiello L., Gardner Th.W., King G.L. Retinopathy in Diabetes. Diabetes Care. 2004; 27(1):84-87. doi:10.2337/diacare.27.2007.s84

11. Barac I.R., Pop M.D., Gheorghe A.I., Taban C. Neovascular secondary glaucoma, etiology and pathogenesis. Rom J Ophthalmol. 2015; 59(1):24–28.

12. Li Y., Hu D., Lv P., Xing M. Expression of platelet-derived growth factor-C in aqueous humor of patients with neovascular glaucoma and its correlation with vascular endothelial growth factor. Eur J Ophthalmol. 2019. doi:10.1177/1120672119832785

13. Mezhnatsional'noe rukovodstvo po glaukome. T. 2. Klinika glaukomy [International Guide to Glaucoma. Volume 2. Clinic of Glaucoma] Ed. E.A. Egorov. Moscow: Ophtalmology; 2016. 184 p. (In Russ.).

14. Lipatov D.V., Chistiakov T.A., Kyzmin A.G. Hypotenzive eficasy of combine therapy in a secondary neovascular glaucoma treatment. Glaucoma. 2010; 4:29-31. (In Russ.).

15. Mirrakhimova S.H. Optimization of surgical treatment of neovascular glaucoma. Point of view. East-West. 2017; 4:49-51. (In Russ.).

16. Kansky D. Klinicheskaya oftal'mologiya: sistematizirovannyi podkhod [Clinical Ophthalmology: A Systematic Approach]. Moscow, Logosphere; 2006. 744 p. (In Russ.).

17. Natsional'noe rukovodstvo po oftal'mologii [National Guide to Ophthalmology] Ed. S.E. Avetisov. Moscow: GEOTAR-Media; 2008. 944 p. (In Russ.).

18. Kim M., Lee C., Payne R., Yue B.Y. Angiogenesis in glaucoma filtration surgery and neovascular glaucoma — a review. Surv Ophthalmol. 2015; 60(6):524-535. doi:10.1016/j.survophthal.2015.04.003

19. Wolf A., von Jagow B., Ulbig M., Haritoglou C. Intracameral injection of bevacizumab for the treatment of neovascular glaucoma. Ophthalmologica. 2011; 226(2):51-56. doi:10.1159/000327364

20. Liu L., Xu Y., Huang Zh., Wang X. Intravitreal ranibizumab injection combined trabeculectomy versus Ahmed valve surgery in the treatment of neovascular glaucoma: assessment of efficacy and complications. BMC Ophthalmol. 2016; 16:65. doi:10.1186/s12886-016-0248-7

21. Xie Zh., Liu H., Du M., Zhu M. Efficacy of ahmed glaucoma valve implantation on neovascular glaucoma. Int J Med Sci. 2019; 16(10): 1371–1376. doi:10.7150/ijms.35267

22. Lipatov D.V., Smirnova N.B., Aleksandrova V.K. Modern algorithm for laser retinal coagulation in diabetic retinopathy. Diabetes mellitus. 2007; 10(3):45. (In Russ.). doi:10.14341/2072-0351-5997

23. Sun J.T., Liang H.J., An M., Wang D.B. Efficacy and safety of intravitreal ranibizumab with panretinal photocoagulation followed by trabeculectomy compared with Ahmed glaucoma valve implantation in neovascular glaucoma. Int J Ophthalmol. 2017; 10(3):400–405. doi:10.18240/IJO.2017.03.12

24. Zhao X., Wang Zh., Yang X. Management of neovascular glaucoma with intravitreal ranibizumab, panretinal photocoagulation, and subsequent 5-fluorouracil augmented trabeculectomy. A case report. Medicine (Baltimore). 2017; 96(25): e7221. doi:10.1097/MD.0000000000007221

25. Elwehidy A.S., Bayoumi N.H.L., Badawi A.E., Hagras Sh.M. Intravitreal ranibizumab with panretinal photocoagulation followed by trabeculectomy versus visco-trabeculotomy in management of neovascular glaucoma. Asia Pac J Ophthalmol (Phila). 2019; 8(4):308–313. doi:10.1097/APO.0000000000000248

26. Yurieva T.N., Kuzmin S.V., Buriy V.V. Laser and cryosurgery of neovascular glaucoma. Bulletin of TSU. 2015; 20(3):723-727. (In Russ.).

27. Schuko A.G., Bronsky D.I., Zayka V.A., Zlobin I.V. Estimate of retina and ciliary body combined cryosurgical operation efficiency by patients with neovascular glaucoma. Practical medicine. 2013; 1-3 (70):36-38. (In Russ.).

28. Boiko E.V., Shishkin M.M., Sukhoterina E.G., Kulikov A.N. Diodelaser transscleral retinopexy versus cryopexy in vitreoretinal surgery. Ophthalmosurgery and therapy. 2001; 1(1):47-52. (In Russ.).

29. Rodrigues G.B., Abe R.Y., Zangalli C., Sodre S.L. Neovascular glaucoma: a review. Int J Retina Vitreous. 2016; 2:26. doi:10.1186/s40942-016-0051-x

30. Yan H. Outcomes of 23-gauge vitrectomy combined with phacoemulsification, panretinal photocoagulation, and trabeculectomy without use of anti-vegf agents for neovascular glaucoma with vitreous hemorrhage. J Ophthalmol. 2016; 3097379. doi:10.1155/2016/3097379

31. Kawabata K., Shobayashi K., Iwao K., Takahashi E. Efficacy and safety of Ex-PRESS® mini shunt surgery versus trabeculectomy for neovascular glaucoma: a retrospective comparative study. BMC Ophthalmol. 2019; 19:75. doi:10.1186/s12886-019-1083-4

32. Shen C.C., Salim S., Du H., Netland P.A. Trabeculectomy versus Ahmed Glaucoma Valve implantation in neovascular glaucoma. Clin Ophthalmol. 2011; 5:281–286. doi:10.2147/OPTH.S16976

33. Im Y.W., Lym H.S., Park C.K., Moon J.I. Comparison of mitomycin C trabeculectomy and Ahmed Valve Implant surgery for neovascular glaucoma. J Korean Ophthalmol Soc. 2004; 45(9):1515-1521.

34. Shinohara Y., Akiyama H., Magori M., Kishi S. Short-term outcomes after EX-PRESS implantation versus trabeculectomy alone in patients with neovascular glaucoma. Clin Ophthalmol. 2017; 11:2207–2213. doi:10.2147/OPTH.S151200

35. Kiuchi Y., Sugimoto R., Nakae K., Saito Y. Trabeculectomy with mitomycin C for treatment of neovascular glaucoma in diabetic patients. Ophthalmologica. 2006; 220(6):383-388. doi:10.1159/000095865

36. Babushkin А.E., Orenburkina О.I., Absalyamov М.Sh., Matukhina Е.N. About surgical treatment of neovascular glaucoma with the use of VEGF inhibitors. Point of view. East-West. 2016; 1:75-80. (In Russ.).

37. Liao N., Li Ch., Jiang H., Fang A. Neovascular glaucoma: a retrospective review from a tertiary center in China. BMC Ophthalmol. 2016; 16:14. doi:10.1186/s12886-016-0190-8

38. Nakatake Sh., Yoshida Sh., Nakao Sh., Arita R. Hyphema is a risk factor for failure of trabeculectomy in neovascular glaucoma: a retrospective analysis. BMC Ophthalmol. 2014; 14:55. doi:10.1186/1471-2415-14-55

39. Bikbov M.M., Khusnitdinov I.I. Results to glaucoma drainage surgery of patients with secondary neovascular glaucoma. Point of view. East– West. 2017; 4:36-40. (In Russ.).

40. Hong Y., Hu Y., Dou H., Wang Ch. Comparison of the safety and efficacy of triple sequential therapy and transscleral cyclophotocoagulation for neovascular glaucoma in the angle-closure stage. Sci Rep. 2018; 8:7074. doi:10.1038/s41598-018-25394-9

41. Lipatov D.V., Chistyakov T.A., Kuzmin A.G. Drainage surgery of secondary glaucoma with rubeosis in patients with diabetes mellitus. RMJ. Clinical Ophthalmology. 2009; 10(4):137-139. (In Russ.).

42. Bikbov M.M., Khusnitdinov I.I. Analysis of hypotensive effect after Ahmed valve implantation in patients with refractory glaucoma. National Journal glaucoma. 2016; 15(3):24-34. (In Russ.).

43. Yalvac I.S., Eksioglu U., Satana B., Duman S. Long-term results of Ahmed glaucoma valve and Molteno implant in neovascular glaucoma. Eye (Lond). 2007; 21(1):65-70. doi:10.1038/sj.eye.6702125

44. Peter A. Netland The ahmed glaucoma valve in neovascular glaucoma (an AOS thesis). Trans Am Ophthalmol Soc. 2009; 107:325–342.

45. Every S.G., Molteno A.C.B., Bevin T.H., Herbison P. Long-term results of Molteno implant insertion in cases of neovascular glaucoma. Arch Ophthalmol. 2006; 124(3):355-360. doi:10.1001/archopht.124.3.355

46. Ye H., Ying T., Weitao S., Ting S. Clinical efficacy analysis of Ahmed glaucoma valve implantation in neovascular glaucoma and influencing factors. A STROBE-compliant article. Medicine (Baltimore). 2017; 96(42):e8350. doi:10.1097/MD.0000000000008350

47. Mastropasqua L., Carpineto P., Ciancaglini M., Zuppardi E. Longterm results of Krupin-Denver valve implants in filtering surgery for neovascular glaucoma. Ophthalmologica. 1996; 210(4):203-206. doi:10.1159/000310709

48. Alvarado J.A., Hollander D.A., Juster R.P., Lee L.C. Ahmed valve implantation with adjunctive mitomycin C and 5-fluorouracil: long-term outcomes. Am J Ophthalmol. 2008; 146(2):276-284. doi:10.1016/j.ajo.2008.04.008

49. Costa V.P., Azuara-Blanco A., Netland P.A., Lesk M.R. Efficacy and safety of adjunctive mitomycin C during Ahmed Glaucoma Valve implantation: a prospective randomized clinical trial. Ophthalmology. 2004; 111(6):1071-1076. doi:10.1016/j.ophtha.2003.09.037

50. Trible J.R., Brown D.B. Occlusive ligature and standardized fenestration of a Baerveldt tube with and without antimetabolites for early postoperative intraocular pressure control. Ophthalmology. 1998; 105(12):2243-2250. doi:10.1016/S0161-6420(98)91223-4

51. WuDunn D., Phan A.D.T., Cantor L.B., Lind J.T. Clinical experience with the Baerveldt 250-mm glaucoma implant. Ophthalmology. 2006; 113(5):766-772. doi:10.1016/j.ophtha.2006.01.049

52. Nikolashin S.I. Features of valvular implantation technique Ahmed systems for surgical treatment of neovascular glaucoma. RMJ. Clinical ophthalmology. 2013; 1-3(70):33-35. (In Russ.).

53. Zhou M., Xu X., Zhang X., Sun X. Clinical outcomes of Ahmed glaucoma valve implantation with or without intravitreal bevacizumab pretreatment for neovascular glaucoma: a systematic review and meta-analysis. J Glaucoma. 2016; 25(7):551-557. doi:10.1097/IJG.0000000000000241

54. Bikbov M.M., Surkova V.K., Husnitdinov I.I., Chaika O.V. Results of implantation of drenaige system Ahmed in patients with refractory glaucoma. RMJ. Clinical Ophthalmology. 2013; 3:98. (In Russ.).

55. Olmos L.C., Lee R.K. Medical and surgical treatment of neovascular glaucoma. Int Ophthalmol Clin. 2011; 51(3):27–36. doi:10.1097/IIO.0b013e31821e5960

56. Ekici F., Waisbourd M., Katz L.J. Current and future of laser therapy in the management of glaucoma. Open Ophthalmol J. 2016; 10:56-67. doi:10.2174/1874364101610010056

57. Ndulue J.K., Rahmatnejad K., Sanvicente C., Wizov Sh.S. Evolution of Cyclophotocoagulation. J Ophthalmic Vis Res. 2018; 13(1):55–61. doi:10.4103/jovr.jovr_190_17

58. Havens Sh.J., Gulati V. Neovascular Glaucoma. Dev Ophthalmol. 2016; 55:196-204. doi:10.1159/000431196

59. Torky M.A., Al Zafiri Y.A., Hagras Sh.M., Khattab A.M. Safety and efficacy of ultrasound ciliary plasty as a primary intervention in glaucoma patients. Int J Ophthalmol. 2019; 12(4):597–602. doi:10.18240/ijo.2019.04.12

60. Benson M.T., Nelson М.E. Cyclocryotherapy: a review of cases over a 10-year period. Br J Ophthalmol. 1990; 74(2):103-105. doi:10.1136/bjo.74.2.103

61. Goldenberg-Cohen N., Bahar I., Ostashinski M., Lusky M. Cyclocryotherapy versus transscleral diode laser cyclophotocoagulation for uncontrolled intraocular pressure. Ophthalmic Surg Lasers Imaging. 2005; 36(4):272-279.

62. Caprioli J., Strang S.L., Spaeth G.L., Poryzees E.H. Cyclocryotherapy in the treatment of advanced glaucoma. Ophthalmology. 1985; 92(7): 947-954. doi:10.1016/s0161-6420(85)33951-9

63. Oguri A., Takahashi E., Tomita G., Yamamoto T. Transscleral cyclophotocoagulation with the diode laser for neovascular glaucoma. Ophthalmic Surg Lasers. 1998; 29(9):722-727.

64. Yi Q.Y., Cai B., Huang J., Chen L.S. Cyclophotocoagulation with an illuminated laser probe under a noncontact wide-angle retinoscope: A modified technique of ciliary body photocoagulation. Indian J Ophthalmol. 2019; 67(4):515-519. doi:10.4103/ijo.IJO_65_18

65. Lima F.E., Magacho L., Carvalho D.M., Susanna R. Jr. A prospective, comparative study between endoscopic cyclophotocoagulation and the Ahmed drainage implant in refractory glaucoma. J Glaucoma. 2004; 13(3):233-7. doi:10.1097/00061198-200406000-00011

66. Delgado M.F., Dickens C.J., Iwach A.G., Novack G.D. Long-term results of noncontact neodymium:yttrium-aluminum-garnet cyclophotocoagulation in neovascular glaucoma. Ophthalmology. 2003; 110(5):895-899. doi:10.1016/S0161-6420(03)00103-9

67. Fokin V.P., Balalin S.V., Efremova T.G., Potapova V.N. Intravitreal introduction of Lucentis and transscleral cyclophotocoagulation in the treatment of neovascular glaucoma in diabetes mellitus. Acta Biomedica Scientifica. 2016; 1-6(112):122-124. (In Russ.).

68. Markova A.A., Grigorieva I.N., Pozdeyeva N.A., Nikolayeva G.A. Histological changes in the ciliary body after contact transscleral cyclophotocoagulation. Health care in Chuvashia. 2019; 3: 37-46. (In Russ.). doi:10.25589 /GIDUV.2019.97.98.005

69. Tan A.M., Chockalingam M., Aquino M.C., Lim Z.I. Micropulse transscleral diode laser cyclophotocoagulation in the treatment of refractory glaucoma. Clin Exp Ophthalmol. 2010; 38(3):266-272. doi:10.1111/j.1442-9071.2010.02238.x

70. Kuchar S., Moster M.R., Reamer C.B., Waisbourd M. Treatment outcomes of micropulse transscleral cyclophotocoagulation in advanced glaucoma. Lasers Med Sci. 2016; 31(2):393-6. doi:10.1007/s10103-015-1856-9

71. Aquino M.C., Barton K., Tan A.M., Sng C. Micropulse versus continuous wave transscleral diode cyclophotocoagulation in refractory glaucoma: a randomized exploratory study. Clin Exp Ophthalmol. 2015; 43(1):40-46. doi:10.1111/ceo.12360

72. Emanuel M.E., Grover D.S., Fellman R.L., Godfrey D.G. Micropulse cyclophotocoagulation: initial results in refractory glaucoma. J Glaucoma. 2017; 26(8):726-729. doi:10.1097/IJG.0000000000000715

73. Jammal A.A., Costa D.C., Vasconcellos J.P.C., Costa V.P. Prospective evaluation of micropulse transscleral diode cyclophotocoagulation in refractory glaucoma: 1 year results. Arq Bras Oftalmol. 2019; 82(5):381-388. doi:10.5935/0004-2749.20190076

74. Eliseeva M.A., Khodzhaev N.S., Sidorova A.V., Starostina A.V. Micropulse transscleral cyclophotocoagulation in the combine surgical treatment of refractory glaucoma: preliminary results. Modern technologies in ophthalmology. 2019; 4:95-98. (In Russ.). doi:10.25276/2312-4911-2019-4-95-98

75. Khodzhaev N.S., Sidorova A.V., Baeva A.V., Smirnova E.A. Transscleral laser treatment of end-stage glaucoma in the micropulse mode: a pilot study. Glaucoma News. 2019; 1 (49):3-5. (In Russ.).

76. Yu A.K., Merrill K.D., Truong S.N., Forward K.M. The comparative histologic effects of subthreshold 532- and 810 nm diode micropulse laser on the retina. Invest Ophthalmol Vis Sci. 2013; 54(3):2216-2224. doi: 10.1167/iovs.12-11382

77. Doga A.V., Kachalina G.F., Gorshkov I.M., Kuranova O.I. Prospects for the use of micropulse laser exposure for macular edema after surgical removal of the epiretinal membrane. Bulletin of Orenburg State University. 2013; 4(153): 71-73. (In Russ.).

78. Gawęcki M. Micropulse laser treatment of retinal diseases. J Clin Med. 2019; 8(2):242. doi:10.3390/jcm8020242

79. Li Z., Song Y., Chen X., Chen Z. Biological modulation of mouse RPE cells in response to subthreshold diode micropulse laser treatment. Cell Biochem Biophys. 2015; 73(2):545-552. doi: 10.1007/s12013-015-0675-8

80. Midena E., Bini S., Frizziero L., Pilotto E. Aqueous humour concentrations of PEDF and Erythropoietin are not influenced by subthreshold micropulse laser treatment of diabetic macular edema. Biosci Rep. 2019; 39(6): BSR20190328. doi:10.1042/BSR20190328

81. Midena E., Micera A., Frizziero L., Pilotto E. Sub-threshold micropulse laser treatment reduces inflammatory biomarkers in aqueous humour of diabetic patients with macular edema. Sci Rep. 2019; 9(1):10034. doi:10.1038/s41598-019-46515-y